Purple Biotech Ltd ADR (PPBT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -6,196 | -3,781 | -19,977 | -15,118 | -10,063 |
| Depreciation Amortization | 97 | 48 | 197 | 149 | 99 |
| Accounts payable and accrued liabilities | -490 | -46 | 1,334 | 415 | -628 |
| Other Working Capital | -1,985 | -930 | 274 | -782 | -2,374 |
| Other Operating Activity | -484 | -373 | -1,753 | 393 | 1,679 |
| Operating Cash Flow | $-9,058 | $-5,082 | $-19,925 | $-14,943 | $-11,287 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 5 | N/A | 15,803 | 15,809 | 15,806 |
| PPE Investments | N/A | N/A | -3 | -3 | -4 |
| Net Acquisitions | N/A | N/A | -3,549 | -3,549 | -3,549 |
| Sale Of Investment | 187 | 187 | 875 | 875 | N/A |
| Other Investing Activity | 207 | 125 | 755 | 675 | 548 |
| Investing Cash Flow | $399 | $312 | $13,881 | $13,807 | $12,801 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 938 | 374 | 6,563 | 1,559 | 881 |
| Other Financing Activity | -237 | -106 | -1,114 | -356 | -250 |
| Financing Cash Flow | $701 | $268 | $5,449 | $1,203 | $631 |
| Exchange Rate Effect | -7 | -2 | 54 | 7 | 27 |
| Beginning Cash Position | 14,489 | 14,489 | 15,030 | 15,030 | 15,030 |
| End Cash Position | 6,524 | 9,985 | 14,489 | 15,104 | 17,202 |
| Net Cash Flow | $-7,965 | $-4,504 | $-541 | $74 | $2,172 |
| Free Cash Flow | |||||
| Operating Cash Flow | -9,058 | -5,082 | -19,925 | -14,943 | -11,287 |
| Capital Expenditure | N/A | N/A | -3 | -3 | -4 |
| Free Cash Flow | -9,058 | -5,082 | -19,928 | -14,946 | -11,291 |